Holen Sie sich die Stockscreener-App
14.09
7.51%
0.97
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
Equities Analysts Offer Predictions for NTLA FY2025 Earnings - MarketBeat
Intellia Therapeutics price target lowered to $55 from $76 at Barclays - MSN
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates - MSN
CF Foundation invests $15M in Recode Therapeutics to boost CF gene editing - Cystic Fibrosis News Today
Intellia Therapeutics Announces Promising CRISPR Therapy Results - Yahoo Finance
Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo - Yahoo Finance
Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade) - Seeking Alpha
Wells Fargo & Company Lowers Intellia Therapeutics (NASDAQ:NTLA) Price Target to $70.00 - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Sees Unusually-High Trading Volume Following Analyst Upgrade - MarketBeat
CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest - BioPharma Dive
Intellia Therapeutics' (NTLA) Neutral Rating Reaffirmed at Wedbush - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $91.00 at Chardan Capital - MarketBeat
Intellia stock touches 52-week low at $13.94 amid biotech slump - Investing.com
Intellia’s gene editing therapy shows early potential in rare heart condition - Clinical Trials Arena
CF Foundation Invests Up to $15 million in ReCode Therapeutics to Develop a Gene Editing Therapy - Yahoo Finance
The Best Biotech Stocks to Buy - Morningstar
Intellia Therapeutics (NASDAQ:NTLA) Reaches New 1-Year LowHere's Why - MarketBeat
Intellia Announces First Clinical Evidence from Ongoing - GlobeNewswire
Intellia's CRISPR Therapy Shows 90%+ Disease Protein Reduction in Key Clinical Trial | NTLA Stock News - StockTitan
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Gene Editing Tools Market Size, Growth Opportunities, - openPR
Sumitomo Mitsui Trust Group Inc. Has $64.72 Million Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics (FRA:38I) Operating Income : €-492.77 Mil (TTM As of Sep. 2024) - GuruFocus.com
When (NTLA) Moves Investors should Listen - Stock Traders Daily
Intellia Therapeutics' SWOT analysis: gene editing stock's progress and potential - Investing.com India
Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more - BioSpace
3 Fast-Growing Stocks Analysts See Doubling in Price - sharewise
Oppenheimer Lowers Intellia Therapeutics (NASDAQ:NTLA) Price Target to $60.00 - MarketBeat
Intellia Therapeutics price target lowered to $60 from $70 at Oppenheimer - TipRanks
Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus (NASDAQ:NTLA) - Seeking Alpha
Brookline Capital Management Forecasts NTLA FY2027 Earnings - MarketBeat
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q3 2024 Earnings Call Transcript - MSN
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at StockNews.com - MarketBeat
NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus - MSN
Intellia Therapeutics (NASDAQ:NTLA) Issues Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates - Yahoo Finance
Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day? - MSN
Intellia Earnings: Early-Stage Pipeline Makes Progress; Shares Attractive for Long-Term Investors - Morningstar
Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $55.00 by Analysts at Barclays - MarketBeat
Intellia Therapeutics Inc (NTLA) Q3 2024 Earnings Call Highlight - GuruFocus.com
Intellia Therapeutics Inc (NTLA) Q3 2024 Earnings Call Highlights: Financial Stability and ... - Yahoo Finance Australia
ARK Investment Management LLC Buys 659,651 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics Reports Q3 2024 Financial Progress - TipRanks
Intellia Therapeutics price target lowered to $40 from $41 at JonesResearch - TipRanks
Intellia Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Intellia Therapeutics Inc earnings beat by $0.05, revenue topped estimates - Investing.com
Intellia Therapeutics reports Q3 EPS ($1.34), consensus ($1.39) - TipRanks
Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress - The Manila Times
Intellia (NTLA) Advances Phase 3 Trials Despite $135.7M Loss; $944.7M Cash Runway to 2026 | NTLA Stock News - StockTitan
Harbor Capital Advisors Inc. Grows Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics (NTLA) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Data UnderwhelmsIntellia's Cash, Data And Competition Are A Challenging Story - Seeking Alpha
This Beaten-Down Stock Could Soar by 354%, According to Wall Street - Yahoo Finance
(NTLA) Long Term Investment Analysis - Stock Traders Daily
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):